Basilea Pharmaceutica Ag Stock Beta
| BSLN Stock | CHF 40.65 0.45 1.09% |
Basilea Pharmaceutica AG fundamentals help investors to digest information that contributes to Basilea Pharmaceutica's financial success or failures. It also enables traders to predict the movement of Basilea Stock. The fundamental analysis module provides a way to measure Basilea Pharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Basilea Pharmaceutica stock.
Basilea |
Basilea Pharmaceutica AG Company Beta Analysis
Basilea Pharmaceutica's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Basilea Pharmaceutica Beta | 0.88 |
Most of Basilea Pharmaceutica's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Basilea Pharmaceutica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Basilea Pharmaceutica AG has a Beta of 0.8761. This indicator is about the same for the Healthcare average (which is currently at 0.86) sector and 36.97% lower than that of the Biotechnology industry. The beta for all Switzerland stocks is notably lower than that of the firm.
Basilea Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basilea Pharmaceutica's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics of similar companies.Basilea Pharmaceutica is currently under evaluation in beta category among its peers.
Basilea Pharmaceutica returns are very sensitive to returns on the market. As the market goes up or down, Basilea Pharmaceutica is expected to follow.
Basilea Fundamentals
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 670.47 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.05 % | |||
| Shares Owned By Institutions | 28.93 % | |||
| Price To Earning | 190.88 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 148.12 M | |||
| Gross Profit | 30.89 M | |||
| EBITDA | 2.11 M | |||
| Net Income | (6.83 M) | |||
| Cash Per Share | 13.81 X | |||
| Total Debt | 94.54 M | |||
| Current Ratio | 5.84 X | |||
| Book Value Per Share | (5.67) X | |||
| Cash Flow From Operations | (32.02 M) | |||
| Earnings Per Share | 0.23 X | |||
| Target Price | 72.33 | |||
| Number Of Employees | 177 | |||
| Beta | 0.88 | |||
| Market Capitalization | 591.36 M | |||
| Total Asset | 247.27 M | |||
| Z Score | 3.6 | |||
| Net Asset | 247.27 M |
About Basilea Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.